RT Journal Article
T1 Breakthrough cancer pain - still a challenge.
A1 Margarit, Cesar
A1 López, Rafael
A1 Anton, Antonio
A1 Escobar, Yolanda
A1 Casas, Ana
A1 Cruz, Juan Jesús
A1 Galvez, Rafael
A1 Mañas, Ana
A1 Zaragozá, Francisco
K1 Prevalence
K1 Management
K1 Diagnosis
K1 Opioids
K1 Prevalencia
K1 Diagnóstico
K1 Analgésicos Opioides
K1 Fentanilo
K1 Pectinas
K1 Dolor intercurrente
AB Breakthrough cancer pain is defined as transient pain exacerbation in patients with stable and controlled basal pain. Although variable, the prevalence of breakthrough cancer pain is high (33%-95%). According to the American Pain Foundation, breakthrough pain is observed in 50%-90% of all hospitalized cancer patients, in 89% of all patients admitted to homes for the elderly and terminal-patient care centers, and in 35% of all ambulatory care cancer patients. The management of breakthrough cancer pain should involve an interdisciplinary and multimodal approach. The introduction of new fentanyl formulations has represented a great advance and has notably improved treatment. Among these, the pectin-based intranasal formulation adjusts very well to the profile of breakthrough pain attacks, is effective, has a good toxicity profile, and allows for convenient dosing - affording rapid and effective analgesia with the added advantage of being easily administered by caregivers when patients are unable to collaborate.
PB Dove Medical Press
YR 2012
FD 2012-11-19
LK http://hdl.handle.net/10668/1420
UL http://hdl.handle.net/10668/1420
LA en
NO Margarit C, Juliá J, López R, Anton A, Escobar Y, Casas A, et al. Breakthrough cancer pain - still a challenge. J Pain Res. 2012,  5:559-66
NO Journal Article;
DS RISalud
RD Apr 7, 2025